{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:43:06Z","timestamp":1792896186598,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H02994"],"award-info":[{"award-number":["18H02994"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Implant Dent"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medication-related osteonecrosis of the jaw (MRONJ), which was first reported as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in bisphosphonate users, is a rare but severe soft and hard tissue disease induced by several types of medications. There has been a deluge of information about MRONJ, such as epidemiology, risk factors, clinical recommendations for dental treatment to prevent it, and treatment strategies in medication-prescribed users. The aim of this study was to comprehensively review recent articles and provide the current scientific information about MRONJ, especially clinical considerations or\u00a0recommendations for dental treatment to prevent its occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The current literature review was mainly based on 14 systematic reviews with or without meta-analysis, 4 position papers, 1 consensus statement, 1 clinical guideline, and 2 clinical reviews regarding MRONJ after a PubMed database and manual searches according to inclusion and exclusion criteria.\u00a0Moreover, 53 articles were selected by manual search in regard to all references from selected articles and other articles identified on the PubMed search, irrespective of publication date, and inclusion and exclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence and prevalence of MRONJ are relatively low, although they are clearly higher in cancer patients receiving high-dose antiresorptive agents or angiogenesis inhibitors rather than osteoporosis patients receiving oral bisphosphonates or denosumab. There are many types of local, systemic, and other risk factors for the development of MRONJ. Clinical recommendations are provided for each clinical situation of patients to prevent MRONJ. There are also treatment strategies for MRONJ in each stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>General dentists should perform appropriate dental treatment to prevent MRONJ in the patients prior to or when receiving medications that could induce MRONJ. Moreover, there are treatment strategies for MRONJ in each stage that oral surgeons could follow. Adequate and updated clinical information regarding MRONJ based on scientific data is required whenever possible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40729-021-00323-0","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:04:39Z","timestamp":1620932679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review"],"prefix":"10.1186","volume":"7","author":[{"given":"Mampei","family":"Kawahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-9987","authenticated-orcid":false,"given":"Shinichiro","family":"Kuroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"issue":"10","key":"323_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"323_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"323_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115\u20137. https:\/\/doi.org\/10.1016\/S0278-2391(03)00720-1.","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"323_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","volume":"68","author":"TL Aghaloo","year":"2010","unstructured":"Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010;68(5):959\u201363. https:\/\/doi.org\/10.1016\/j.joms.2009.10.010.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"323_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","volume":"48","author":"KH Taylor","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48(3):221\u20133. https:\/\/doi.org\/10.1016\/j.bjoms.2009.08.030.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"24","key":"323_CR6","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","volume":"26","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26(24):4037\u20138. https:\/\/doi.org\/10.1200\/JCO.2007.15.5424.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","volume":"127","author":"R King","year":"2019","unstructured":"King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(4):289\u201399. https:\/\/doi.org\/10.1016\/j.oooo.2018.11.012.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"323_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","volume":"16","author":"RA Miksad","year":"2011","unstructured":"Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011;16(1):121\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2010-0183.","journal-title":"Oncologist."},{"issue":"1","key":"323_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017;20(1):8\u201324. https:\/\/doi.org\/10.1016\/j.jocd.2016.09.005.","journal-title":"J Clin Densitom"},{"issue":"25","key":"323_CR10","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270\u201390. https:\/\/doi.org\/10.1200\/JCO.19.01186.","journal-title":"J Clin Oncol"},{"issue":"11","key":"323_CR11","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 2010;123(11):1060\u20134. https:\/\/doi.org\/10.1016\/j.amjmed.2010.04.033.","journal-title":"Am J Med"},{"key":"323_CR12","doi-asserted-by":"publisher","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25:e326\u201336. https:\/\/doi.org\/10.4317\/medoral.23324.","DOI":"10.4317\/medoral.23324"},{"issue":"1","key":"323_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","volume":"72","author":"M Ulmner","year":"2014","unstructured":"Ulmner M, Jarnbring F, T\u00f6rring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72(1):76\u201382. https:\/\/doi.org\/10.1016\/j.joms.2013.06.221.","journal-title":"J Oral Maxillofac Surg"},{"key":"323_CR14","doi-asserted-by":"publisher","unstructured":"Svejda B, Muschitz C, Gruber R, Brandtner C, Svejda C, Gasser RW, et al.\u00a0 [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr.\u00a02016;166(1\u20132):68\u201374. https:\/\/doi.org\/10.1007\/s10354-016-0437-2.","DOI":"10.1007\/s10354-016-0437-2"},{"issue":"3","key":"323_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415\u201323. https:\/\/doi.org\/10.1016\/j.joms.2006.10.061.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"323_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181\u20138. https:\/\/doi.org\/10.1007\/s10549-010-0866-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"323_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27(2):383\u201394. https:\/\/doi.org\/10.1007\/s00520-018-4501-x.","journal-title":"Support Care Cancer"},{"issue":"2","key":"323_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, et al. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). J Bone Miner Res. 2016;31(2):336\u201340. https:\/\/doi.org\/10.1002\/jbmr.2693.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"323_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","volume":"43","author":"M Viviano","year":"2017","unstructured":"Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg. 2017;43(2):120\u20134. https:\/\/doi.org\/10.5125\/jkaoms.2017.43.2.120.","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"323_CR20","doi-asserted-by":"publisher","unstructured":"Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F. Regorafenib also can cause osteonecrosis of the jaw. J Natl Cancer Inst. 2016;108(4):djw002. https:\/\/doi.org\/10.1093\/jnci\/djw002.","DOI":"10.1093\/jnci\/djw002"},{"issue":"4","key":"323_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/adj.12254","volume":"60","author":"R Marino","year":"2015","unstructured":"Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2015;60(4):528\u201331. https:\/\/doi.org\/10.1111\/adj.12254.","journal-title":"Aust Dent J"},{"issue":"4","key":"323_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcms.2013.05.014","volume":"42","author":"A Allegra","year":"2014","unstructured":"Allegra A, Oteri G, Alonci A, Bacci F, Penna G, Minardi V, et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg. 2014;42(4):279\u201382. https:\/\/doi.org\/10.1016\/j.jcms.2013.05.014.","journal-title":"J Craniomaxillofac Surg"},{"issue":"12","key":"323_CR23","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/j.joms.2017.05.016","volume":"75","author":"P Keribin","year":"2017","unstructured":"Keribin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the jaw in a patient presenting with post-transplantation lymphoproliferative disorder treated with rituximab: a case report. J Oral Maxillofac Surg. 2017;75(12):2599\u2013605. https:\/\/doi.org\/10.1016\/j.joms.2017.05.016.","journal-title":"J Oral Maxillofac Surg"},{"key":"323_CR24","doi-asserted-by":"publisher","unstructured":"Sacco R, Shah S, Leeson R, Moraschini V, de Almeida Barros Mour\u00e3o CF, Akintola O, et al. Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-\u03b1) inhibitors: a systematic review. Br J Oral Maxillofac Surg. 2020;58:25\u201333. https:\/\/doi.org\/10.1016\/j.bjoms.2019.09.023.","DOI":"10.1016\/j.bjoms.2019.09.023"},{"issue":"16","key":"323_CR25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1607948.","journal-title":"N Engl J Med"},{"issue":"5","key":"323_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","volume":"44","author":"R Fliefel","year":"2015","unstructured":"Fliefel R, Tr\u00f6ltzsch M, K\u00fchnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44(5):568\u201385. https:\/\/doi.org\/10.1016\/j.ijom.2015.01.026.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"9768","key":"323_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6.","journal-title":"Lancet."},{"issue":"35","key":"323_CR28","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.7101.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24(4):527\u201336. https:\/\/doi.org\/10.1111\/odi.12708.","journal-title":"Oral Dis"},{"issue":"1","key":"323_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6\u201319. https:\/\/doi.org\/10.1007\/s00774-016-0810-7.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"323_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1563\/aaid-joi-D-18-00032","volume":"44","author":"S Yamamoto","year":"2018","unstructured":"Yamamoto S, Maeda K, Kouchi I, Hirai Y, Taniike N, Yamashita D, et al. Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. J Oral Implantol. 2018;44(5):359\u201364. https:\/\/doi.org\/10.1563\/aaid-joi-D-18-00032.","journal-title":"J Oral Implantol"},{"issue":"8","key":"323_CR32","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","volume":"29","author":"M Pazianas","year":"2007","unstructured":"Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29(8):1548\u201358. https:\/\/doi.org\/10.1016\/j.clinthera.2007.08.008.","journal-title":"Clin Ther"},{"issue":"6","key":"323_CR33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A Badros","year":"2006","unstructured":"Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24(6):945\u201352. https:\/\/doi.org\/10.1200\/JCO.2005.04.2465.","journal-title":"J Clin Oncol"},{"key":"323_CR34","doi-asserted-by":"publisher","unstructured":"Sandro Pereira da Silva J, Pullano E, Raje NS, Troulis MJ, August M. Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review. Int J Oral Maxillofac Surg. 2019;48:1289\u201399. https:\/\/doi.org\/10.1016\/j.ijom.2019.04.014.","DOI":"10.1016\/j.ijom.2019.04.014"},{"issue":"4","key":"323_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11005\/jbm.2015.22.4.151","volume":"22","author":"KM Kim","year":"2015","unstructured":"Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2015;22(4):151\u201365. https:\/\/doi.org\/10.11005\/jbm.2015.22.4.151.","journal-title":"J Bone Metab"},{"issue":"3","key":"323_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","volume":"12","author":"J Yamashita","year":"2012","unstructured":"Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3):233\u201347. https:\/\/doi.org\/10.1016\/S1532-3382(12)70046-5.","journal-title":"J Evid Based Dent Pract"},{"issue":"5","key":"323_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1532-5415.2011.03371.x","volume":"59","author":"JC Lo","year":"2011","unstructured":"Lo JC, O'Ryan F, Yang J, Hararah MK, Gonzalez JR, Gordon N, et al. Oral health considerations in older women receiving oral bisphosphonate therapy. J Am Geriatr Soc. 2011;59(5):916\u201322. https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03371.x.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"323_CR38","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243\u201351. https:\/\/doi.org\/10.14219\/jada.archive.2011.0108.","journal-title":"J Am Dent Assoc"},{"issue":"Suppl 18","key":"323_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/clr.13282","volume":"29","author":"A Stavropoulos","year":"2018","unstructured":"Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schi\u00f8dt M, Klinge B. The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res. 2018;29(Suppl 18):54\u201392. https:\/\/doi.org\/10.1111\/clr.13282.","journal-title":"Clin Oral Implants Res"},{"key":"323_CR40","doi-asserted-by":"publisher","unstructured":"Romero-Ruiz MM, Romero-Serrano M, Serrano-Gonz\u00e1lez A, Serrera-Figallo MA, Guti\u00e9rrez-P\u00e9rez JL, Torres-Lagares D. Proposal for a preventive protocol for medication-related osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020:24197. https:\/\/doi.org\/10.4317\/medoral.24197.","DOI":"10.4317\/medoral.24197"},{"issue":"11","key":"323_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.oraloncology.2014.08.016","volume":"50","author":"K Rupel","year":"2014","unstructured":"Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049\u201357. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.08.016.","journal-title":"Oral Oncol"},{"issue":"Suppl 16","key":"323_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/clr.13288","volume":"29","author":"M Schimmel","year":"2018","unstructured":"Schimmel M, Srinivasan M, McKenna G, M\u00fcller F. Effect of advanced age and\/or systemic medical conditions on dental implant survival: a systematic review and meta-analysis. Clin Oral Implants Res. 2018;29(Suppl 16):311\u201330. https:\/\/doi.org\/10.1111\/clr.13288.","journal-title":"Clin Oral Implants Res"},{"issue":"5","key":"323_CR43","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/clr.12088","volume":"25","author":"TG Kwon","year":"2014","unstructured":"Kwon TG, Lee CO, Park JW, Choi SY, Rijal G, Shin HI. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2014;25(5):632\u201340. https:\/\/doi.org\/10.1111\/clr.12088.","journal-title":"Clin Oral Implants Res"},{"issue":"12","key":"323_CR44","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jcms.2016.09.018","volume":"44","author":"M Troeltzsch","year":"2016","unstructured":"Troeltzsch M, Cagna D, St\u00e4hler P, Probst F, Kaeppler G, Ehrenfeld M, et al. Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis? J Craniomaxillofac Surg. 2016;44(12):1945\u201351. https:\/\/doi.org\/10.1016\/j.jcms.2016.09.018.","journal-title":"J Craniomaxillofac Surg"},{"issue":"3","key":"323_CR45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/jop.12963","volume":"49","author":"AI Lorenzo-Pouso","year":"2020","unstructured":"Lorenzo-Pouso AI, P\u00e9rez-Say\u00e1ns M, Chamorro-Petronacci C, G\u00e1ndara-Vila P, L\u00f3pez-Jornet P, Carballo J, et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Oral Pathol Med. 2020;49(3):190\u2013200. https:\/\/doi.org\/10.1111\/jop.12963.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"323_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jpor.2014.08.001","volume":"59","author":"K Niibe","year":"2015","unstructured":"Niibe K, Ouchi T, Iwasaki R, Nakagawa T, Horie N. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodont Res. 2015;59(1):3\u20135. https:\/\/doi.org\/10.1016\/j.jpor.2014.08.001.","journal-title":"J Prosthodont Res"},{"issue":"11","key":"323_CR47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567\u201375. https:\/\/doi.org\/10.1016\/j.joms.2005.07.010.","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"323_CR48","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.ajpath.2014.07.010","volume":"184","author":"DW Williams","year":"2014","unstructured":"Williams DW, Lee C, Kim T, Yagita H, Wu H, Park S, et al. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-\u03baB ligand antibody in mice. Am J Pathol. 2014;184(11):3084\u201393. https:\/\/doi.org\/10.1016\/j.ajpath.2014.07.010.","journal-title":"Am J Pathol"},{"issue":"3","key":"323_CR49","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.bone.2012.04.020","volume":"51","author":"C Pautke","year":"2012","unstructured":"Pautke C, Kreutzer K, Weitz J, Kn\u00f6dler M, M\u00fcnzel D, Wexel G, et al. Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model. Bone. 2012;51(3):592\u20139. https:\/\/doi.org\/10.1016\/j.bone.2012.04.020.","journal-title":"Bone."},{"issue":"1","key":"323_CR50","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","volume":"177","author":"Y Bi","year":"2010","unstructured":"Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010;177(1):280\u201390. https:\/\/doi.org\/10.2353\/ajpath.2010.090592.","journal-title":"Am J Pathol"},{"issue":"9","key":"323_CR51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1600-0714.2010.00927.x","volume":"39","author":"P L\u00f3pez-Jornet","year":"2010","unstructured":"L\u00f3pez-Jornet P, Camacho-Alonso F, Molina-Mi\u00f1ano F, G\u00f3mez-Garc\u00eda F, Vicente-Ortega V. An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. J Oral Pathol Med. 2010;39(9):697\u2013702. https:\/\/doi.org\/10.1111\/j.1600-0714.2010.00927.x.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"323_CR52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2013.05.013","volume":"56","author":"S Kuroshima","year":"2013","unstructured":"Kuroshima S, Yamashita J. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice. Bone. 2013;56(1):101\u20139. https:\/\/doi.org\/10.1016\/j.bone.2013.05.013.","journal-title":"Bone."},{"key":"323_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bone.2018.05.001","volume":"112","author":"S Kuroshima","year":"2018","unstructured":"Kuroshima S, Sasaki M, Nakajima K, Tamaki S, Hayano H, Sawase T. Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. Bone. 2018;112:177\u201386. https:\/\/doi.org\/10.1016\/j.bone.2018.05.001.","journal-title":"Bone."},{"key":"323_CR54","doi-asserted-by":"publisher","unstructured":"Hayano H, Kuroshima S, Sasaki M, Tamaki S, Inoue M, Ishisaki A, et al. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. Bone. 2020;135:115308. https:\/\/doi.org\/10.1016\/j.bone.2020.115308.","DOI":"10.1016\/j.bone.2020.115308"},{"issue":"6","key":"323_CR55","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.joms.2012.11.016","volume":"71","author":"MR Allen","year":"2013","unstructured":"Allen MR, Chu TM, Ruggiero SL. Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone. J Oral Maxillofac Surg. 2013;71(6):1017\u201326. https:\/\/doi.org\/10.1016\/j.joms.2012.11.016.","journal-title":"J Oral Maxillofac Surg"},{"issue":"9","key":"323_CR56","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/jbmr.2490","volume":"30","author":"RS de Molon","year":"2015","unstructured":"de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, et al. OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice. J Bone Miner Res. 2015;30(9):1627\u201340. https:\/\/doi.org\/10.1002\/jbmr.2490.","journal-title":"J Bone Miner Res"},{"key":"323_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bone.2016.06.011","volume":"90","author":"A Soundia","year":"2016","unstructured":"Soundia A, Hadaya D, Esfandi N, de Molon RS, Bezouglaia O, Dry SM, et al. Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease. Bone. 2016;90:133\u201341. https:\/\/doi.org\/10.1016\/j.bone.2016.06.011.","journal-title":"Bone."},{"issue":"4","key":"323_CR58","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/jbmr.2097","volume":"29","author":"TL Aghaloo","year":"2014","unstructured":"Aghaloo TL, Cheong S, Bezouglaia O, Kostenuik P, Atti E, Dry SM, et al. RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J Bone Miner Res. 2014;29(4):843\u201354. https:\/\/doi.org\/10.1002\/jbmr.2097.","journal-title":"J Bone Miner Res"},{"key":"323_CR59","doi-asserted-by":"publisher","unstructured":"Moraschini V, Calasans-Maia MD, Louro RS, Arantes EBR, Calasans-Maia JA. Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses. J Oral Pathol Med. 2021;50:10\u201321. https:\/\/doi.org\/10.1111\/jop.13083. Epub 2020 Jul 12.","DOI":"10.1111\/jop.13083"},{"issue":"7","key":"323_CR60","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.joms.2009.03.005","volume":"67","author":"FS O'Ryan","year":"2009","unstructured":"O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67(7):1363\u201372. https:\/\/doi.org\/10.1016\/j.joms.2009.03.005.","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"323_CR61","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","volume":"117","author":"M Schiodt","year":"2014","unstructured":"Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(2):204\u201313. https:\/\/doi.org\/10.1016\/j.oooo.2013.10.010.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"323_CR62","doi-asserted-by":"publisher","unstructured":"Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Sedghizadeh PP. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep. 2010;8(1):40\u20138. https:\/\/doi.org\/10.1007\/s11914-010-0008-1.","DOI":"10.1007\/s11914-010-0008-1"},{"issue":"4","key":"323_CR63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.joms.2007.11.035","volume":"66","author":"PP Sedghizadeh","year":"2008","unstructured":"Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66(4):767\u201375. https:\/\/doi.org\/10.1016\/j.joms.2007.11.035.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"323_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.oooo.2012.08.446","volume":"115","author":"G Wanger","year":"2013","unstructured":"Wanger G, Gorby Y, El-Naggar MY, Yuzvinsky TD, Schaudinn C, Gorur A, et al. Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(1):71\u20138. https:\/\/doi.org\/10.1016\/j.oooo.2012.08.446.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"10","key":"323_CR65","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/jbmr.3191","volume":"32","author":"S Hayashida","year":"2017","unstructured":"Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, et al. Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the Factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res. 2017;32(10):2022\u20139. https:\/\/doi.org\/10.1002\/jbmr.3191.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"323_CR66","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677\u201392. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020.","journal-title":"Bone."},{"key":"323_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, et al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11\u20137. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003.","journal-title":"Bone."},{"issue":"1","key":"323_CR68","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00774-019-01035-7","volume":"38","author":"S Hayashida","year":"2020","unstructured":"Hayashida S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab. 2020;38(1):126\u201334. https:\/\/doi.org\/10.1007\/s00774-019-01035-7.","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"323_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","volume":"30","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int. 2019;30(1):231\u20139. https:\/\/doi.org\/10.1007\/s00198-018-4746-8.","journal-title":"Osteoporos Int"},{"issue":"4","key":"323_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03795","volume":"6","author":"C Ottesen","year":"2020","unstructured":"Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): a systematic review. Heliyon. 2020;6(4):e03795. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e03795.","journal-title":"Heliyon."},{"key":"323_CR71","doi-asserted-by":"publisher","unstructured":"Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, et al. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(2):195\u2013202. https:\/\/doi.org\/10.1016\/j.tripleo.2011.02.037.","DOI":"10.1016\/j.tripleo.2011.02.037"},{"issue":"2","key":"323_CR72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/annonc\/mdn630","volume":"20","author":"T Van den Wyngaert","year":"2009","unstructured":"Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20(2):331\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdn630.","journal-title":"Ann Oncol"},{"key":"323_CR73","doi-asserted-by":"publisher","unstructured":"Bodem JP, Schaal C, Kargus S, Saure D, Mertens C, Engel M, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(4):367\u201372. https:\/\/doi.org\/10.1016\/j.oooo.2015.10.033.","DOI":"10.1016\/j.oooo.2015.10.033"},{"key":"323_CR74","doi-asserted-by":"publisher","unstructured":"Martins AS, Correia JA, Salvado F, Caldas C, Santos N, Capelo A, et al. Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws\u2014a retrospective cohort study. J Craniomaxillofac Surg. 2017;45(10):1736\u201342. https:\/\/doi.org\/10.1016\/j.jcms.2017.07.014.","DOI":"10.1016\/j.jcms.2017.07.014"},{"key":"323_CR75","doi-asserted-by":"publisher","unstructured":"Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, et al. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2012;34(2):194\u2013200. https:\/\/doi.org\/10.1002\/hed.21708.","DOI":"10.1002\/hed.21708"}],"container-title":["International Journal of Implant Dentistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40729-021-00323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40729-021-00323-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40729-021-00323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:12:21Z","timestamp":1620933141000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalimplantdent.springeropen.com\/articles\/10.1186\/s40729-021-00323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1186\/s40729-021-00323-0","relation":{},"ISSN":["2198-4034"],"issn-type":[{"value":"2198-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mampei Kawahara, Shinichiro Kuroshima, and Takashi Sawase declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}